Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Xbrane Biopharma AB ( (SE:XBRANE) ) has issued an announcement.
Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company that develops biological drugs using a patented platform technology designed to reduce production costs compared to other systems. The company has a portfolio of biosimilar candidates targeting significant market opportunities, with its lead candidate Ximluci® already granted market authorization in Europe. Xbrane is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 18,368,001
Current Market Cap: SEK383.7M
Find detailed analytics on XBRANE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue